Find your future career

What drives us and what we do - Stay up to date with all the happenings at Grünenthal


12 Jan 2017

Grünenthal introduces Latin America’s most modern women’s health products plant

Santiago de Chile, Chile – January 12th, 2017: Grünenthal, an R&D-driven, privately owned international pharmaceutical company with headquarters in Germany, announced the introduction of its new women’s health products plant today. Grünenthal invested USD 14.5 million to build the 1,150 m2 hormone plant, which is the company’s center of excellence for hormone production and the most modern in Latin America. The new facility will initially deliver high quality women’s health products to the Chilean market and – after the pending approval of the relevant authorities (INVIMA/ANVISA/COFEPRIS) – it will also provide products for other Latin American markets, including the biggest of the region: Brazil and Mexico. With this investment Grünenthal will improve the access of more than 168 million Latin American women to high quality health products.

More ...

16 Dec 2016

Grünenthal receives Breakthrough Therapy Designation from U.S. FDA for neridronic acid for the treatment of complex regional pain syndrome (CRPS), a debilitating orphan disease with high medical need

Aachen, Germany, and Pisa, Italy – 16 December 2016 – Grünenthal, an R&D-driven, privately held international pharmaceutical company with headquarters in Germany, and Abiogen Pharma, privately held Italian pharmaceutical company with headquarter in Pisa, Italy announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to neridronic acid, an investigational medicine, for the treatment of complex regional pain syndrome (CRPS), a serious, disabling orphan disease. Today, with no FDA- or EMA-approved drug treatments, there is a clear need for effective treatment options to address this significant unmet medical need. CRPS is a debilitating condition characterized by severe, continuous, burning pain often occurring in an extremity after injury or surgery. It is one of the most painful conditions a patient can experience1.

More ...

12 Dec 2016

Grünenthal to acquire commercialization rights of Qutenza® in Europe from Astellas Pharma Europe

Aachen, December 12, 2016. Grünenthal Group today announced that it has entered into a definitive agreement with Astellas Pharma Europe Ltd., (“Astellas Pharma Europe”), the European subsidiary of Tokyo-based Astellas Pharma Inc. (“Astellas”), for the exclusive rights to the dermal patch Qutenza® (capsaicin 8%) in Europe, Middle East and Africa. Qutenza® is approved by the European Medicines Agency (EMA) for the treatment of peripheral neuropathic pain (PNP).

More ...

16 Nov 2016

Grünenthal has acquired US-based Thar Pharmaceuticals Inc. to expand its development portfolio of treatment options for CRPS (Complex Regional Pain Syndrome), a serious, disabling orphan disease.

Aachen, Germany, and Pittsburgh, PA, USA – 16 November 2016 – Grünenthal, an R&D-driven, privately held international pharmaceutical company with headquarters in Germany, has announced its recent acquisition of Thar Pharmaceuticals, a US-based clinical-stage, specialty pharmaceutical company. Thar Pharmaceuticals focused on transforming IV-only drugs into oral drugs for existing and new indications using its proprietary technology EnhanceTM development platform. With this acquisition, Grünenthal has obtained the worldwide development and commercialization rights for Thar Pharmaceutical’s lead development candidate, T121.

More ...

previous [10]